NY-SULLIVAN-&-CROMWELL
3.1.2022 15:48:09 CET | Business Wire | Press release
Sullivan & Cromwell LLP announced today that Robert J. Giuffra, Jr. and Scott Miller have become Co-Chairs of the firm, effective January 1, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005204/en/
Mr. Giuffra and Mr. Miller have served as Vice Chairs of the firm since January 2021. They succeed Joseph C. Shenker, the firm’s Chair since 2010, who will continue to serve on the firm’s Management Committee as Senior Chair in addition to continuing with his active client practice.
“Since the days of our founders, Sullivan & Cromwell has an unwavering commitment to our clients, our people and our communities,” said Mr. Shenker. “Bob and Scott exemplify these qualities, long ago establishing themselves as trusted counselors whose complementary strengths in litigation and corporate law reflect the broad scope of work we do for our clients around the world.”
“Our firm’s international practice and ability to deliver integrated client service through our network of 13 offices across four continents are critical to our success,” said Mr. Miller. “More than half of our firm’s clients are headquartered outside the United States, and Bob and I have each spent our careers handling our clients’ most complex cross-border matters. As the world becomes even more integrated and the issues clients face become more complex, we expect our global practice to be a driver of our firm’s continued success.”
“I am honored to work with Scott and our partners to build on our firm’s strong culture of excellence, innovation and commitment to our clients and each other,” said Mr. Giuffra. “For 143 years, our model has been tried and true: to recruit and train the best lawyers to work together to help our clients solve their most critical challenges and capture their highest value opportunities.”
Mr. Giuffra, a nationally prominent litigator, joined S&C in 1989 after serving as a law clerk to Chief Justice William Rehnquist of the U.S. Supreme Court and Judge Ralph Winter of the U.S. Court of Appeals for the Second Circuit. Based in New York, he has been a member of Sullivan & Cromwell’s Management Committee since 2007. A fellow of the American College of Trial Lawyers and International Academy of Trial Lawyers, he has successfully represented the firm’s clients in multi-billion dollar trials, litigations and government investigations. He has played a significant role in navigating some of the biggest corporate crises of the past 20 years, including the bankruptcy of Enron, the accounting frauds at Computer Associates and HealthSouth Corporation, the financial crisis, and the Volkswagen diesel emissions crisis for which he served as the carmaker’s national coordinating counsel. His current clients include Allianz, Goldman Sachs, Stellantis, UBS and Volkswagen. He has represented corporate boards and directors, CEOs, senior public officials, prominent families, law firms and professional sports teams.
Mr. Miller, a premier corporate counselor, joined S&C in 1986 after serving as a law clerk to Judge William A. Norris of the U.S. Court of Appeals for the Ninth Circuit. He routinely handles multi-billion dollar M&A, capital markets and other strategic transactions, internal and government investigations and other corporate crises. Now based in New York, he has been a member of the Firm’s Management Committee since 2014 and coordinates our U.S. and European corporate practices. He has worked on M&A and securities transactions in more than 20 countries, including the first privatization in Italy and the first German LBO. He represented Fiat Chrysler in its $60 billion merger with Peugeot, which transformed the global auto industry through the creation of Stellantis. Earlier, he represented Fiat in connection with its 2009 rescue of Chrysler, Ferrari in its 2015 IPO, and Alcan in fighting off a hostile takeover offer from Alcoa and in its $46 billion acquisition by Rio Tinto. He has represented DISH Network for two decades and recently in a series of transactions that helped it form and fund its nationwide wireless communications network. He has also recently been in the forefront of the SPAC market, representing among others DraftKings in its de-SPAC listing and other acquisitions and financings to create one of the world’s largest digital sports entertainment and gaming companies and Ermenegildo Zegna Group in its merger with a SPAC sponsored by Investindustrial through which Zegna became a NYSE-listed company, with an initial market capitalization in excess of $3 billion.
Mr. Giuffra is a graduate of Princeton University and Yale Law School. He has served as Chief Counsel of the U.S. Senate Banking Committee and as President of the Federal Bar Council. He is a member of New York’s Permanent Commission on Access to Justice and the Standing Committee on Rules of Practice and Procedure of the U.S. Courts. He is chair of the American Swiss Foundation.
Mr. Miller is a graduate of Arizona State University and Columbia Law School. He was managing partner of Sullivan & Cromwell’s Palo Alto office and has been resident in the firm’s London and Los Angeles offices. He is a trustee of the United States Council for International Business.
About Sullivan & Cromwell LLP
Sullivan & Cromwell LLP is a global law firm that advises on significant litigation, corporate investigations and complex regulatory, major domestic and cross-border M&A, finance, corporate and restructuring transactions, tax and estate planning matters. Founded in 1879, Sullivan & Cromwell has approximately 900 lawyers located in offices in New York, Washington, Los Angeles, Palo Alto, London, Frankfurt, Paris, Brussels, Hong Kong, Beijing, Tokyo, Melbourne and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005204/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
